Gangagen Biotechnologies Private LIMITED
Bengaluru, KA
- UEI
- FCHHM8JKZNE6
- CAGE
- 3345Y
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- Tumkur Rd, Yeswanthpur, Bengaluru, Karnataka, India
- Website
- gangagen.com
- Founded
- 2001
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | $4,687,082 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Curza Inc. | Salt Lake City, UT | — |
| Basilea Pharmaceutica International Ltd, Allschwil | Allschwil, BL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Debiopharm International SA | Lausanne, VD | — |
| Entasis Therapeutics, Inc. | Waltham, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Arietis Corporation | Boston, MA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Gangagen Biotechnologies Private LIMITED is a biotechnology company specializing in developing products for preventing and treating bacterial infections, including antibiotic-resistant strains. According to its website description, their innovative approach combines molecular and clinical sciences, inspired by nature to design novel anti-infective medicines.
Through federal sub-contract awards, Gangagen Biotechnologies Private LIMITED has provided research and development services aimed at designing and developing bacteriocins as antibacterial agents. Specifically, they have worked on discovering potent klebicin molecules that exhibit antibacterial activity against Klebsiella pneumoniae, a major Gram-negative pathogen responsible for causing pneumonia and rapidly becoming resistant to current antibiotics. Their work has involved screening protein antibiotics to identify hit molecules that can kill K. pneumoniae in test tubes and protect mice from lethal lung infections. These sub-contract awards were funded through prime contracts awarded to Trustees of Boston University by agencies supporting research on combating antibiotic resistance.
Through federal sub-grant awards, Gangagen Biotechnologies Private LIMITED has also provided research and development services focused on designing and developing bacteriocins as antibacterial agents. Their grant-funded work has centered on further discovery and development of more potent klebicin molecules for treating hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by K. pneumoniae. This sub-grant award was funded through a prime grant awarded to Trustees of Boston University by CARB-X, a partnership dedicated to accelerating antibacterial research to combat the global rising threat of drug-resistant bacteria.
Quick answers
Is Gangagen Biotechnologies Private LIMITED registered in SAM.gov?
Yes. Gangagen Biotechnologies Private LIMITED's SAM.gov registration is active through November 25, 2026.
On GovTribe
See Gangagen Biotechnologies Private LIMITED's full federal record
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors